

Jose M Garcia Acuña

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7237902/publications.pdf>

Version: 2024-02-01

106
papers

1,991
citations

236612

25
h-index

301761

39
g-index

114
all docs

114
docs citations

114
times ranked

2773
citing authors

#	ARTICLE	IF	CITATIONS
1	Differences Between Takotsubo and the Working Diagnosis of Myocardial Infarction With Nonobstructive Coronary Arteries. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 742010.	1.1	4
2	Sex differences in the management of patients with acute coronary syndrome: A population-based ecological cross-sectional study in Spain. <i>REC: CardioClinics</i> , 2021, 56, 168-178.	0.1	3
3	Prognostic benefit from an early invasive strategy in patients with non-ST elevation acute coronary syndrome (NSTEMI): evaluation of the new risk stratification in the NSTEMI European guidelines. <i>Clinical Research in Cardiology</i> , 2021, 110, 1464-1472.	1.5	2
4	Early revascularization and long-term mortality in high-risk patients with non-ST-elevation myocardial infarction. The CARDIOCHUS-HUSJ registry. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 35-42.	0.4	6
5	Long-term bleeding risk vs. mortality risk in acute coronary syndrome patients according to the 2019 ARC-HBR definition. <i>Thrombosis Research</i> , 2020, 196, 516-518.	0.8	9
6	Sex-related differences in long-term mortality and heart failure in a contemporary cohort of patients with NSTEMI. The cardiochus-HSUJ registry. <i>European Journal of Internal Medicine</i> , 2020, 81, 26-31.	1.0	7
7	The different roles for the advanced glycation end products axis in heart failure and acute coronary syndrome settings. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 1050-1060.	1.1	14
8	<p>A prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation population</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 371-380.	0.9	20
9	Short–and Long–Term Prognosis of Patients With Takotsubo Syndrome Based on Different Triggers: Importance of the Physical Nature. <i>Journal of the American Heart Association</i> , 2019, 8, e013701.	1.6	65
10	Prevalence and outcomes of atrial fibrillation in a European healthcare area gained through the processing of a health information technology system. <i>Revista Portuguesa De Cardiologia</i> , 2019, 38, 21-29.	0.2	7
11	S–ndrome de tako-tsubo complicado con taponamiento cardiaco y shock cardiogãnico. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 351-353.	0.6	0
12	Incidence and predictors of stroke in patients discharged with the diagnosis of acute coronary syndrome. <i>International Journal of Cardiology</i> , 2019, 276, 20-25.	0.8	11
13	Temporal trends between association of evidence-based treatment and outcomes in patients with non-ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2018, 260, 1-6.	0.8	8
14	Association of Beta-Blockers with Survival on Patients Presenting with ACS Treated with PCI: A Propensity Score Analysis from the BleeMACS Registry. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 299-309.	1.0	8
15	Prediction of Post-Discharge Bleeding in Elderly Patients with Acute Coronary Syndromes: Insights from the BleeMACS Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 929-938.	1.8	19
16	Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: The BleeMACS score. <i>International Journal of Cardiology</i> , 2018, 254, 10-15.	0.8	66
17	Determinantes e impacto pronãstico de la insuficiencia cardiaca y la fracciãn de eyecciãn del ventrãculo izquierdo en el sãndrome coronario agudo. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 820-828.	0.6	13
18	Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 631-638.	0.4	82

#	ARTICLE	IF	CITATIONS
19	Daño cardiaco en paciente con enfermedad de Behçet. Integración diagnóstica y terapéutica. Revista Española De Cardiología, 2018, 71, 1075-1077.	0.6	2
20	Short- and Long-Term Prognostic Relevance of Cardiogenic Shock in Takotsubo Syndrome. JACC: Heart Failure, 2018, 6, 928-936.	1.9	86
21	A multicentre randomized pilot trial on the effectiveness of different levels of cooling in comatose survivors of out-of-hospital cardiac arrest: the FROST-I trial. Intensive Care Medicine, 2018, 44, 1807-1815.	3.9	49
22	Relevance of Dementia in Atrial Fibrillation Patients within a Specific European Health Care Area. Neuroepidemiology, 2018, 51, 11-18.	1.1	3
23	Gender-related differences in post-discharge bleeding among patients with acute coronary syndrome on dual antiplatelet therapy: A BleeMACS sub-study. Thrombosis Research, 2018, 168, 156-163.	0.8	17
24	Prevalence, long-term prognosis and medical alternatives for patients admitted for acute coronary syndromes and prasugrel contraindication. International Journal of Cardiology, 2018, 270, 36-41.	0.8	9
25	Omentin treatment of epicardial fat improves its anti-inflammatory activity and paracrine benefit on smooth muscle cells. Obesity, 2017, 25, 1042-1049.	1.5	22
26	Proposal of a novel clinical score to predict heart failure incidence in long-term survivors of acute coronary syndromes. International Journal of Cardiology, 2017, 249, 301-307.	0.8	7
27	Clinical profile and outcomes in octogenarians with atrial fibrillation: A community-based study in a specific European health care area. International Journal of Cardiology, 2017, 243, 211-215.	0.8	21
28	Additive value of the CRUSADE score to the GRACE score for mortality risk prediction in patients with acute coronary syndromes. International Journal of Cardiology, 2017, 245, 1-5.	0.8	21
29	Optimal Medical Therapy in Patients with Malignancy Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome: a BleeMACS Sub-Study. American Journal of Cardiovascular Drugs, 2017, 17, 61-71.	1.0	12
30	BleeMACS. Journal of Cardiovascular Medicine, 2016, 17, 744-749.	0.6	27
31	Glucose and Inflammatory Cells Decrease Adiponectin in Epicardial Adipose Tissue Cells: Paracrine Consequences on Vascular Endothelium. Journal of Cellular Physiology, 2016, 231, 1015-1023.	2.0	22
32	Alteration of platelet GPVI signaling in ST-elevation myocardial infarction patients demonstrated by a combination of proteomic, biochemical, and functional approaches. Scientific Reports, 2016, 6, 39603.	1.6	14
33	Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction. Revista Portuguesa De Cardiologia, 2016, 35, 645-653.	0.2	12
34	Impact of blood transfusion on in-hospital myocardial infarctions according to patterns of acute coronary syndrome: Insights from the BleeMACS registry. International Journal of Cardiology, 2016, 221, 364-370.	0.8	13
35	Safety and effectiveness of the new P2Y12r inhibitor agents vs clopidogrel in ACS patients according to the geographic area: East Asia vs Europe. International Journal of Cardiology, 2016, 220, 488-495.	0.8	8
36	El riesgo de eventos cardiovasculares tras un evento coronario agudo persiste elevado a pesar de la revascularización, especialmente durante el primer año. Revista Española De Cardiología, 2016, 69, 11-18.	0.6	81

#	ARTICLE	IF	CITATIONS
37	Dominancia coronaria y pronóstico a largo plazo de los pacientes con infarto de miocardio con elevación del segmento ST tratado con angioplastia primaria. Revista Espanola De Cardiologia, 2016, 69, 19-27.	0.6	17
38	Mehran contrast nephropathy risk score: Is it still useful 10 years later?. Journal of Cardiology, 2016, 67, 262-267.	0.8	41
39	Risk stratification for the development of heart failure after acute coronary syndrome at the time of hospital discharge: Predictive ability of GRACE risk score. Journal of Cardiology, 2015, 66, 224-231.	0.8	15
40	¿En la era actual existe beneficio pronóstico del tratamiento con bloqueadores beta tras un síndrome coronario agudo con función sistólica conservada?. Revista Espanola De Cardiologia, 2015, 68, 585-591.	0.6	26
41	Prognostic Benefit of Beta-blockers After Acute Coronary Syndrome With Preserved Systolic Function. Still Relevant Today?. Revista Espanola De Cardiologia (English Ed), 2015, 68, 585-591.	0.4	11
42	Relation of Contrast Induced Nephropathy to New Onset Atrial Fibrillation in Acute Coronary Syndrome. American Journal of Cardiology, 2015, 115, 587-591.	0.7	10
43	Pronóstico a largo plazo de pacientes con infarto agudo de miocardio sin elevación del segmento ST y arterias coronarias sin estenosis significativa. Revista Espanola De Cardiologia, 2015, 68, 777-784.	0.6	4
44	Clinical Treatment and Prognosis in Patients With Acute Coronary Syndrome and Anemia. Response. Revista Espanola De Cardiologia (English Ed), 2015, 68, 356.	0.4	0
45	Impacto de la fibrilación ventricular que complica el curso de un síndrome coronario agudo en la incidencia a largo plazo de muerte súbita cardiaca. Revista Espanola De Cardiologia, 2015, 68, 878-884.	0.6	5
46	Noninvasive Treatment of Acute Myocardial Infarction. Clinical Profile and Predictors of Poor Prognosis. Revista Espanola De Cardiologia (English Ed), 2015, 68, 343-345.	0.4	4
47	Tratamiento no invasivo del infarto agudo de miocardio. Perfil clínico de los pacientes y variables predictoras de mal pronóstico. Revista Espanola De Cardiologia, 2015, 68, 343-345.	0.6	6
48	Tratamiento clínico y pronóstico en pacientes con síndrome coronario agudo y anemia. Respuesta. Revista Espanola De Cardiologia, 2015, 68, 356.	0.6	0
49	Advanced glycation end-products as long-term predictors of death and reinfarction after an acute coronary syndrome. Biomarkers in Medicine, 2015, 9, 209-216.	0.6	8
50	Impact of Acute Coronary Syndrome Complicated by Ventricular Fibrillation on Long-term Incidence of Sudden Cardiac Death. Revista Espanola De Cardiologia (English Ed), 2015, 68, 878-884.	0.4	3
51	Mortality and cardiovascular morbidity within 30 days of discharge following acute coronary syndrome in a contemporary European cohort of patients: How can early risk prediction be improved? The six-month GRACE risk score. Revista Portuguesa De Cardiologia, 2015, 34, 383-391.	0.2	12
52	Control de la glucemia en el paciente crónico. Revista Espanola De Cardiologia Suplementos, 2015, 15, 3-7.	0.2	2
53	Is 6-month GRACE risk score a useful tool to predict stroke after an acute coronary syndrome?. Open Heart, 2014, 1, e000123.	0.9	8
54	Therapeutic Strategy in Patients With Severe Anemia Admitted for Non-ST-segment Elevation Acute Coronary Syndrome and Prognostic Impact. Revista Espanola De Cardiologia (English Ed), 2014, 67, 1058-1059.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Relative performance of three formulas to assess renal function at predicting in-hospital hemorrhagic complications in an acute coronary syndrome population. What does the new CKD-EPI formula provide?. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014, 3, 237-245.	0.4	13
56	Contrast-induced nephropathy and bleeding: A bidirectional link with prognostic value in acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014, 176, 235-236.	0.8	2
57	Usefulness of the QRS-T Angle to Improve Long-Term Risk Stratification of Patients With Acute Myocardial Infarction and Depressed Left Ventricular Ejection Fraction. <i>American Journal of Cardiology</i> , 2014, 113, 1312-1319.	0.7	39
58	Miocardio patías. Clasificación. <i>Medicine</i> , 2013, 11, 2495-2499.	0.0	0
59	Miocardio patía restrictiva. <i>Medicine</i> , 2013, 11, 2516-2523.	0.0	0
60	Incidence and prognostic value of infections during an acute coronary syndrome: A single center experience. <i>International Journal of Cardiology</i> , 2013, 168, 1609.	0.8	0
61	Miocardio patía dilatada. <i>Medicine</i> , 2013, 11, 2500-2506.	0.0	0
62	Results of Intra-aortic Balloon Counterpulsation in Patients With ST-elevation Myocardial Infarction With Cardiogenic Shock Undergoing Percutaneous Coronary Intervention: Is There a Benefit?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 590-591.	0.4	0
63	High-sensitivity C-reactive protein predicts adverse outcomes after non-ST-segment elevation acute coronary syndrome regardless of GRACE risk score, but not after ST-segment elevation myocardial infarction. <i>Revista Portuguesa De Cardiologia</i> , 2013, 32, 117-122.	0.2	20
64	Statins modulate feedback regulation mechanisms between advanced glycation end-products and C-reactive protein: Evidence in patients with acute myocardial infarction. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 512-518.	1.9	9
65	Creatinine or cystatin C-based equations to estimate glomerular filtration rate in acute myocardial infarction: A disparity in estimating renal function and in mortality risk prediction. <i>International Journal of Cardiology</i> , 2013, 168, 4300-4301.	0.8	9
66	Prognostic influence of prior ischemic heart disease in in-hospital mortality of acute coronary syndromes. <i>International Journal of Cardiology</i> , 2013, 168, 5063-5064.	0.8	0
67	A comparison of the CKD-EPI, MDRD-4, and Cockcroft-Gault equations to assess renal function in predicting all-cause mortality in acute coronary syndrome patients. <i>International Journal of Cardiology</i> , 2013, 167, 2325-2326.	0.8	17
68	GRACE Risk Score Predicts Contrast-Induced Nephropathy in Patients With Acute Coronary Syndrome and Normal Renal Function. <i>Angiology</i> , 2013, 64, 31-39.	0.8	33
69	Resultados del uso del balón de contrapulsación en el shock cardiogénico secundario a infarto agudo de miocardio sometido a revascularización coronaria percutánea: ¿hay beneficio?. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 590-591.	0.6	3
70	Relative performance of three formulas to assess renal function at predicting in-hospital hemorrhagic complications in acute coronary syndrome population. What does the new CKD-EPI formula provide?. <i>European Heart Journal</i> , 2013, 34, 4412-4412.	1.0	0
71	Analysis of the obesity paradox according to the sex: relation between body mass index and mortality in the first year after an acute coronary syndrome. <i>European Heart Journal</i> , 2013, 34, P713-P713.	1.0	0
72	Comparative performance of glomerular filtrate rate estimated by creatinine, cystatin C or both to predict contrast induced nephropathy in acute coronary syndrome. <i>European Heart Journal</i> , 2013, 34, P4039-P4039.	1.0	0

#	ARTICLE	IF	CITATIONS
73	Dosing of iodinated contrast volume: A new simple algorithm to stratify the risk of contrast-induced nephropathy in patients with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 888-897.	0.7	17
74	Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 877-884.	2.9	27
75	A new simple algorithm to stratify the risk of contrast-induced nephropathy in patients with acute coronary syndrome. <i>European Heart Journal</i> , 2013, 34, 4410-4410.	1.0	0
76	Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome. <i>PLoS ONE</i> , 2013, 8, e74302.	1.1	41
77	High-Sensitivity C-Reactive Protein is a Predictor of In-Hospital Cardiac Events in Acute Myocardial Infarction Independently of GRACE Risk Score. <i>Angiology</i> , 2012, 63, 30-34.	0.8	21
78	Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2012, 1, 222-231.	0.4	68
79	Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report. <i>Cardiovascular Diabetology</i> , 2012, 11, 102.	2.7	25
80	Walking Beyond the GRACE (Global Registry of Acute Coronary Events) Model in the Death Risk Stratification During Hospitalization in Patients With Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1117-1125.	1.1	23
81	Letter by Raposeiras-Roubán et al Regarding Article, "Mortality Associated With Atrial Fibrillation in Patients With Myocardial Infarction: A Systematic Review and Meta-Analysis". <i>Circulation</i> , 2011, 124, e483; author's reply e484.	1.6	3
82	Validación en una cohorte contemporánea de pacientes con síndrome coronario agudo del score GRACE predictor de mortalidad a los 6 meses de seguimiento. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 640-648.	0.6	40
83	Admission and fasting plasma glucose for estimating risk of death of diabetic and nondiabetic patients with acute coronary syndrome: nonlinearity of hazard ratios and time-dependent comparison. <i>American Heart Journal</i> , 2009, 158, 989-997.	1.2	34
84	Cystatin C Provides More information Than Other Renal Function Parameters for Stratifying Risk in Patients With Acute Coronary Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 510-519.	0.4	10
85	La cistatina C aporta más información que otros parámetros de función renal en la estratificación del riesgo de los pacientes con síndrome coronario agudo. <i>Revista Espanola De Cardiologia</i> , 2009, 62, 510-519.	0.6	31
86	Evolution of Hepatorenal Syndrome After Orthotopic Liver Transplantation: Comparative Analysis With Patients Who Developed Acute Renal Failure in the Early Postoperative Period of Liver Transplantation. <i>Transplantation Proceedings</i> , 2007, 39, 2318-2319.	0.3	7
87	Acute pulmonary edema in patients with decompensated heart failure. Role of underlying cardiopathy on the prognosis. <i>International Journal of Cardiology</i> , 2007, 121, 302-305.	0.8	4
88	Anaemia is associated with higher mortality among patients with heart failure with preserved systolic function. <i>Heart</i> , 2005, 92, 780-784.	1.2	28
89	The death rate among hospitalized heart failure patients with normal and depressed left ventricular ejection fraction in the year following discharge: evolution over a 10-year period. <i>European Heart Journal</i> , 2005, 26, 2251-2258.	1.0	43
90	Long-Term Trends in Drug Prescription for Hospitalized Patients With Congestive Heart Failure. Influence of Type of Dysfunction. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2005, 58, 381-388.	0.4	1

#	ARTICLE	IF	CITATIONS
91	Dissección coronaria espontánea: aspectos diagnósticos y terapéuticos. Medicina Intensiva, 2003, 27, 188-190.	0.4	1
92	Desaparición del generador de marcapasos. Revista Espanola De Cardiologia, 2003, 56, 407-407.	0.6	0
93	La fibrilación auricular permanente en las enfermedades cardiovasculares en España. Estudio CARDIOTENS 1999. Revista Espanola De Cardiologia, 2002, 55, 943-952.	0.6	59
94	Impacto de la hipertensión en las cardiopatías en España. Estudio CARDIOTENS 1999. Revista Espanola De Cardiologia, 2001, 54, 139-149.	0.6	82
95	Infarto agudo de miocardio y trombosis coronaria inducidos por cocaína. Medicina Intensiva, 2000, 24, 30-32.	0.4	1
96	Step-Down of Enalapril Treatment for Arterial Hypertension. Hypertension, 1999, 34, 1287-1292.	1.3	5
97	Haemodynamic performance of aortic pericardial bioprostheses and bileaflet prostheses at rest and during exercise: implications for the surgical management of patients with small aortic roots. Heart, 1999, 82, 149-155.	1.2	7
98	Maintenance of blood pressure control and left ventricular performance with small doses of enalapril. American Journal of Cardiology, 1999, 83, 719-723.	0.7	3
99	Effects on Left Ventricular Mass and Function of Low Doses of Enalapril for Systemic Hypertension. American Journal of Cardiology, 1998, 81, 87-90.	0.7	2
100	Reduction of QT and QTc Dispersion During Long-Term Treatment of Systemic Hypertension With Enalapril. American Journal of Cardiology, 1998, 81, 170-174.	0.7	65
101	Evolution of Left Ventricular Hypertrophy and Function During Long-Term Treatment of Systemic Hypertension With Enalapril. American Journal of Cardiology, 1997, 79, 373-376.	0.7	9
102	Influence of the size of aortic valve prostheses on hemodynamics and change in left ventricular mass: Implications for the surgical management of aortic stenosis. Journal of Thoracic and Cardiovascular Surgery, 1996, 112, 273-280.	0.4	98
103	Plasma leukocyte elastase concentration in angiographically diagnosed coronary artery disease. European Heart Journal, 1995, 16, 615-622.	1.0	31
104	Left ventricular systolic function after marked reduction of ventricular hypertrophy induced by 5 years' enalapril treatment. European Heart Journal, 1995, 16, 1981-1987.	1.0	11
105	Doppler Echocardiographic Comparison of Small (19 mm) Bileaflet and Pericardial Heart Valve Prostheses in Aortic Position. Scandinavian Journal of Thoracic and Cardiovascular Surgery, 1995, 29, 29-35.	0.2	10
106	Treatment of Massive Pulmonary Thromboembolism with Low Intrapulmonary Dosages of Urokinase. Chest, 1992, 102, 341-346.	0.4	30